ANDA 40731, held by Sun Pharm Inds. Phenytoin Sodium.
As of Nov 16, 2026, ANDA 40731 (Extended Phenytoin Sodium), held by Sun Pharm Inds, was first approved by FDA on Jun 30, 2008, with 3 approved supplements and 0 published complete response letters.
Extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 2008 | Original application | Approved | None posted |
| Extended Phenytoin Sodium200MG EXTENDED · capsule;oral | Phenytoin Sodium | Discontinued |
| Extended Phenytoin Sodium300MG EXTENDED · capsule;oral | Phenytoin Sodium | Discontinued |
| Mar 28, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Mar 28, 2023 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jan 21, 2010 | Supplement 2Labeling | Approved | None posted |
| Jun 30, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters